Cargando…

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180

Bullous pemphigoid (BP) is a common autoimmune blistering disease in which autoantibodies target the hemidesmosomal components BP180 and/or BP230 in basal keratinocytes. In BP, 80 to 90% of autoantibodies target the juxtamembranous extracellular non-collagenous 16th A (NC16A) domain of BP180. Recent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mai, Yosuke, Nishie, Wataru, Izumi, Kentaro, Shimizu, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549357/ https://www.ncbi.nlm.nih.gov/pubmed/31191560 http://dx.doi.org/10.3389/fimmu.2019.01224

Ejemplares similares

A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors
por: Izumi, Kentaro, et al.
Publicado: (2019)

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
por: Mai, Yosuke, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
por: Kawaguchi, Yohei, et al.
Publicado: (2018)

Association of Autoantibodies to BP180 with Disease Activity in Greek Patients with Bullous Pemphigoid
por: Patsatsi, Aikaterini, et al.
Publicado: (2012)

BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid
por: Liu, Yale, et al.
Publicado: (2017)

The significance of preclinical anti-BP180 autoantibodies
por: Mai, Yosuke, et al.
Publicado: (2022)

Evaluation of ELISA BP180 and BP230 Autoantibodies in Blister Fluid and Serum in the Diagnosis of Bullous Pemphigoid
por: Nagarajan, Harish, et al.
Publicado: (2023)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Biochip detection of BP180 autoantibodies in blister fluid for the serodiagnosis of bullous pemphigoid: A pilot study
por: Sernicola, Alvise, et al.
Publicado: (2019)

Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases
por: Csorba, Kinga, et al.
Publicado: (2011)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid()()
por: Gravani, Agoritsa, et al.
Publicado: (2021)

Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid
por: Cole, Connor, et al.
Publicado: (2022)

Native Autoantigen Complex Detects Pemphigoid Autoantibodies
por: Mai, Shoko, et al.
Publicado: (2023)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors: A report of five cases
por: Yoshiji, Satoshi, et al.
Publicado: (2017)

Evaluation of the Role of BIOCHIP Mosaic Based Indirect Immunofluorescence and ELISA BP 180 and BP 230 Autoantibodies in the Diagnosis of Bullous Pemphigoid Patients
por: Nithya, VPS, et al.
Publicado: (2022)

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor – A case report
por: Karthik, S, et al.
Publicado: (2019)

A Cross-Sectional Study to Correlate Disease Severity in Bullous Pemphigoid Patients with Serum Levels of Autoantibodies Against BP180 and BP230
por: Muhammed, Naziya, et al.
Publicado: (2021)

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients
por: Nätynki, Antti, et al.
Publicado: (2022)

Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

Analysis of the autoimmune response against BP180 and BP230 in ethnic Poles with neurodegenerative disorders and bullous pemphigoid
por: Gornowicz-Porowska, Justyna, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
por: Pasmatzi, Efi, et al.
Publicado: (2011)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
por: Kinyó, Ágnes, et al.
Publicado: (2021)

Pemphigoid Nodularis Induced by Long-Term Use of Dipeptidyl Peptidase-4 Inhibitors
por: Norikawa, Natsumi, et al.
Publicado: (2023)

Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
por: Kridin, Khalaf, et al.
Publicado: (2022)

Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome
por: SUGIYAMA, Seiko, et al.
Publicado: (2020)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
por: Lambadiari, Vaia, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
por: Hung, Chih-Tsung, et al.
Publicado: (2022)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
por: Balighi, Kamran, et al.
Publicado: (2022)

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
por: Nozawa, Keisuke, et al.
Publicado: (2023)

Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor–induced bullous pemphigoid
por: Yamashita, Chigusa, et al.
Publicado: (2021)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
por: Shinohara, Yasutake, et al.
Publicado: (2020)

Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patients
por: Gasparini, Giulia, et al.
Publicado: (2023)

Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid
por: Lee, Eui Hyung, et al.
Publicado: (2012)

The Localization of Bullous Pemphigoid Antigen 180 (BP180) in Hemidesmosomes Is Mediated by Its Cytoplasmic Domain and Seems to be Regulated by the β4 Integrin Subunit
por: Borradori, Luca, et al.
Publicado: (1997)

Molecular genetic studies of a human epidermal autoantigen (the 180-kD bullous pemphigoid antigen/BP180): identification of functionally important sequences within the BP180 molecule and evidence for an interaction between BP180 and alpha 6 integrin
Publicado: (1995)

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
por: Bukvić Mokos, Zrinka, et al.
Publicado: (2020)

Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul
por: Ugurer, Ece, et al.
Publicado: (2022)

Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance
por: Tukaj, Stefan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bk44s355m1e5ds4g6se090m049